NCT03445780

Brief Summary

The purpose of this study is to evaluate the best distraction mechanism during trigger finger injection in the outpatient setting. Temporary discomfort from the needle prick is highly feared by patients and is often accompanied by significant acute pain and distress during routine corticosteroid injection in the orthopedic outpatient setting. This study aims to examine 4 different distraction methods and their efficacy in reducing perceived pain, which will be evaluate using the VAS (visual analog pain score.) The three distraction methods will be ethyl chloride spray, adjacent pinch, ethyl chloride spray and pinch, and "screen" or looking away method.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2019

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 13, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 26, 2018

Completed
1.3 years until next milestone

Study Start

First participant enrolled

June 1, 2019

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2020

Completed
Last Updated

January 27, 2020

Status Verified

January 1, 2020

Enrollment Period

10 months

First QC Date

February 13, 2018

Last Update Submit

January 22, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Visual Analog Scale (VAS) Score

    A 10-cm scale will be shown to the patients, and they will be asked to choose the proper number, with 1 representing no pain and 10 symbolizing the most pain imaginable

    1 Minute, 24 Hours

Study Arms (4)

First Group

EXPERIMENTAL

Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection

Drug: Ethyl chloride spray

Second Group

EXPERIMENTAL

The skin between the distal palmar crease and the palmo-digital crease and the palmo-digital crease will be pinched for 5 seconds prior to injection

Procedure: Pinching

Third Group

EXPERIMENTAL

Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection as well as a second pinch to the skin between the distal palmar crease and the palmo digital crease

Drug: Ethyl chloride sprayProcedure: Pinching

Fourth Group

EXPERIMENTAL

Subjects will sit behind a screen with a small opening large enough to introduce the injection hand. They will not see any of the procedure.

Procedure: No Site of Procedure

Interventions

Skin cooling with ethyl chloride spray 5 seconds prior to injection

Also known as: Bethamethasone
First GroupThird Group
PinchingPROCEDURE

Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection

Second GroupThird Group

Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure

Fourth Group

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of Trigger Finger

You may not qualify if:

  • Allergies to lidocaine, betamethasone, infection, pregnancy, 3 prior injection to the digit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York University School of Medicine

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Trigger Finger Disorder

Condition Hierarchy (Ancestors)

Tendon EntrapmentTendinopathyMuscular DiseasesMusculoskeletal Diseases

Study Officials

  • Eitan Melamed, MD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 13, 2018

First Posted

February 26, 2018

Study Start

June 1, 2019

Primary Completion

April 1, 2020

Study Completion

April 1, 2020

Last Updated

January 27, 2020

Record last verified: 2020-01

Locations